-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1787 Outcomes of Patients with IDH1/2 Mutated Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Era of IDH Inhibitors

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Adult, MPN, Clinical Research, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Myeloid Malignancies, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Leah A Goldberg, MD1*, James J. Yoon, MD2, Hannah Johnston, MD3, Marta Beata Davidson, MD, PhD4, Alexa Siddon, M.D.5*, Rory M. Shallis, MD6, Evan C. Chen, MD7, Madelyn Burkart, M.D.8, Timothy S. Oh, MD8*, Sunil G. Iyer, MD9, Ellen Madarang, PharmD10*, Chandrasekar Muthiah, MD11, Joshua Kassner, MD12*, Raajit Rampal, MD, PhD13, Guru Subramanian Guru Murthy, MBBS14, Terrence Bradley, MD15, Yasmin Abaza, MD16, Jacqueline S. Garcia, MD17, Vikas Gupta, MD, FRCP, FRCPath18, Kristen M. Pettit, MD19, Olatoyosi Odenike, MD20, John F. Cursio, PhD21* and Anand Ashwin Patel, MD20

1Department of Internal Medicine, University of Chicago Medical Center, Chicago, IL
2University of Michigan, Ann Arbor, MI
3Section of Hematology/Oncology, The University of Chicago, Chicago, IL
4Leukemia program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada
5Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT
6Department of Internal Medicine, Section of Hematology, Yale School of Medicine - Yale Cancer Center, Killingworth, CT
7Adult Leukemia Program, Medical Oncology, Medford, MA
8Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
9Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
10Leukemia Service, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL
11Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI
12Department of Internal Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, NY
13Memorial Sloan Kettering Cancer Center, New York, NY
14Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
15University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
16Northwestern University, Chicago, IL
17Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
18The Princess Margaret Cancer Centre, Toronto, ON, Canada
19Department of Internal Medicine, Division of Hematology/Oncology, C.S. Mott Children's Hospital, Ann Arbor, MI
20Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
21University of Chicago Biological Sciences Division, Chicago, IL

Introduction: Myeloproliferative neoplasms (MPN) carry a variable risk of progression to accelerated phase (AP) or blast phase (BP), which is associated with poor overall survival (OS). Isocitrate dehydrogenase (IDH) mutations are associated with the progression of MPNs to AP/BP and are characterized as high-risk mutations. The IDH1 inhibitors ivosidenib and olutasidenib and the IDH2 inhibitor enasidenib are approved for use in acute myeloid leukemia (AML) and reports have demonstrated the efficacy of IDH inhibition in IDH1/2-mutated MPN AP/BP (Patel et al, BJH 2020; Chifotides et al, Blood Adv 2020, Gangat et al, BJH 2023). Our group previously reported on a cohort of 202 patients (pts) diagnosed with MPN AP/BP with modern myeloid therapies and found a median OS (mOS) of 0.86 years (Patel et al, Blood Adv 2024); here we describe the treatment patterns and survival of pts with IDH1/2-mutated MPN AP/BP.

Methods: In this multicenter, retrospective study, adult pts with IDH1/2-mutated MPN AP/BP diagnosed after 1/1/2017 were included. Patient demographic, disease characteristics, treatment, and survival data were collected. Response was characterized by European LeukemiaNet (ELN) 2017 criteria and 2012 MPN-BP criteria. OS was evaluated with Kaplan-Meier analysis.

Results: Thirty-five pts with IDH1/2-mutated MPN AP/BP were identified (9 with AP, 26 with BP). Median age was 69.5 years old and 54% were male. Thirty pts had race and ethnicity data, of which 90% identified as White and 4% identified as Hispanic. MPN AP/BP arose from polycythemia vera in 20% of pts, essential thrombocythemia in 26%, primary myelofibrosis in 26%, MPN not otherwise specified in 23% and other in 5%. Regarding incidence of driver mutations, JAK2 was noted in 74% of pts, MPL in 9%, CALR in 9% and 11% were triple-negative. Ten pts (29%) underwent allogeneic stem cell transplant for MPN AP/BP.

All pts underwent next generation sequencing (NGS) at diagnosis of MPN AP/BP; 11 (31%) had an IDH1 mutation and 24 (69%) had an IDH2 mutation. Non-driver co-mutations with frequency >10% included SRSF2 (43%), ASXL1 (37%), DNMT3A (17%), TP53 (17%), TET2 (14%), and EZH2 (11%). Thirty pts had at least 1 adverse risk mutation by ELN 2022 criteria.

We then analyzed responses based on frontline (1L) treatment approach along with survival for the entire cohort and stratified by 1L treatment. By ELN 2017 criteria a response was characterized as achievement of complete remission (CR), CR with incomplete count recovery (CRi), or partial remission (PR). Ten pts received intensive chemotherapy (IC) with an overall response rate (ORR) of 40% (3 CR, 1 CRi). For hypomethylating agent (HMA) + venetoclax (VEN)-based therapy (HMA+VEN) (n=9) ORR was 67% (2 CR, 4 CRi), for HMA-based therapy (HMA monotherapy or HMA+JAKi) (n=8) ORR was 50% (3 CRi, 1 PR), and for IDH inhibitor (IDHi)-based (HMA+IDHi or IDHi), (n=6) the ORR was 33% (1 CRi, 1 PR).

Response by 2012 MPN-BP criteria in pts with available data was also reported. Response was characterized by achievement of complete molecular response (CMR), complete cytogenetic response (CCR), acute leukemia response (ALR)-complete (ALR-C), or ALR-partial (ALR-P). ORR were 57% (1 CCR, 3 ALR-C) with IC (n=7), 57% (3 ALR-C, 1 ALR-P) with HMA + VEN (n=7), 50%(2 ALR-C, 2 ALR-P) with HMA-based (n=8) and 67% (1 ALR-C, 3 ALR-P) with IDHi-based (n=6).

Median OS (mOS) for the entire cohort was 2.2 years; of note the mOS for pts (n=30) with 1+ ELN22 adverse-risk co-mutations was 2.6 years. Median OS by frontline therapy was 1.5 years for IC, 1.1 years for HMA + VEN, 2.2 years for HMA-based, and 2 years for IDHi-based with no statistically significant difference (p=0.9976).

We also analyzed outcomes of IDHi-based therapy in the relapsed/refractory (R/R) setting. Eight pts received IDHi-based therapy (1 IDH1 and 7 IDH2) with an ORR of 25% by ELN2017 (2 CRi). When using 2012 MPN-BP criteria, ORR was 50% (2 ALR-C, 2 ALR-P). Median OS from time of IDHi initiation in the R/R setting was 1.1 years.

Conclusions: In our cohort of pts with IDH1/2-mutated MPN-AP/BP, mOS was 2.2 years and was not impacted by the presence of adverse-risk ELN22 mutations. There was no significant difference in mOS based on frontline treatment, although mOS was numerically longest in the HMA-based and IDH inhibitor based groups. IDH inhibitors also retained efficacy in the R/R setting with an ALR-C/ALR-P rate of 50% and mOS of 1.1 years.

Disclosures: Shallis: Servier: Consultancy, Honoraria, Other: Steering Commitee; Rigel: Consultancy, Honoraria; Kura Oncology: Consultancy, Honoraria; Gilead Sciences, Inc: Consultancy, Honoraria. Chen: AbbVie: Consultancy; Rigel: Consultancy. Iyer: MorphoSys: Membership on an entity's Board of Directors or advisory committees. Rampal: Zentalis: Consultancy, Research Funding; Kartos: Consultancy; Servier: Consultancy; Disc Medicine: Consultancy; Cogent: Consultancy; Sumitomo Dainippon: Consultancy; Ryvu: Research Funding; Constellation/MorphoSys: Consultancy, Research Funding; Karyopharm: Consultancy; Jazz Pharmaceuticals: Consultancy; Protagonist: Consultancy; Sierra Oncology/GSK: Consultancy; Jubilant: Consultancy; PharmaEssentia: Consultancy; Galecto: Consultancy; Stemline Therapeutics: Consultancy, Research Funding; CTI BioPharma: Consultancy; AbbVie: Consultancy; Blueprint: Consultancy; Celgene/BMS: Consultancy; Incyte Corporation: Consultancy, Research Funding; Novartis: Consultancy; Promedior: Consultancy. Guru Murthy: Gilead Sciences/Kite: Other: Advisory board, Research Funding; Merck: Research Funding; BMS: Other: Advisory Board; Amgen: Consultancy, Speakers Bureau; LOXO/Lilly: Research Funding; Autolus: Other: Advisory board; Zentalis: Research Funding; Syndax: Other: Advisory Board; Rigel: Speakers Bureau; Stemline: Speakers Bureau; BeiGene: Other: Advisory board, Research Funding; Schrodinger: Research Funding; Pfizer: Other: Advisory board. Bradley: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees; Geron Corporation: Membership on an entity's Board of Directors or advisory committees. Abaza: Kite/Gilead: Consultancy; Pfizer: Consultancy; Servier: Consultancy; Astellas: Consultancy; Rigel: Consultancy; BMS/Celgene: Consultancy; Geron: Consultancy; ALX Oncology: Research Funding; Biosight: Research Funding; Curis: Research Funding; Novartis: Research Funding; Biomea Fusion: Research Funding; AbbVie: Research Funding; Daiichi-Sankyo: Consultancy; Servier: Consultancy. Garcia: Newave: Research Funding; Servier: Consultancy; Taiho: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Research Funding. Gupta: GSK: Consultancy, Honoraria, Other: support for attending meetings and/or travel; Incyte: Consultancy, Other: Participation on a data safety or advisory board; Constellation: Consultancy; Sierra Oncology: Consultancy, Other: Participation on a data safety or advisory board; Novartis: Consultancy; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Other: Participation on a data safety or advisory board; Sumitomo Pharm: Consultancy; Pfizer: Consultancy, Other: Participation on a data safety or advisory board; BMS/Celgene: Consultancy, Other: Participation on a data safety or advisory board; Roche: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Consultancy, Other: Participation on a data safety or advisory board. Pettit: AbbVie: Consultancy, Research Funding; Incyte: Consultancy; PharmaEssentia: Consultancy; Protagonist Therapeutics: Consultancy, Research Funding; Sierra Oncology: Consultancy; Blueprint Medicines: Research Funding; BMS: Research Funding; Kura Oncology: Research Funding; Imago: Research Funding; Merck: Research Funding. Odenike: AbbVie (Inst); Agios (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Ins: Research Funding; AbbVie; Blueprint Medicines; BMS; Bristol-Myers Squibb/Celgene (Inst); Celgene; CTI; Impact Biomedicines; Kymera; Novartis; SERVIER; Taiho Pharmaceutical; Treadwell Therapeutics: Honoraria. Patel: Bristol Myers Squibb: Honoraria; Pfizer: Research Funding; Sobi: Honoraria; AbbVie: Honoraria; Sumitomo: Research Funding; Kronos Bio: Research Funding.

*signifies non-member of ASH